PROCEPT BioRobotics Corporation Common Stock (PRCT)
Stock · NASDAQ · Health Care
$17.57as of 10/16/2026
Price chart
Active signals
PRCT Signal Track Record
How signals performed across all stocks →What PRCT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -0.9% | 47% | August 4, 2026 |
| Bollinger Band Breakout | 24 | -1.2% | 42% | September 4, 2026 |
| Bollinger Band Breakdown | 22 | -1.8% | 50% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -6.0% | 33% | January 24, 2025 |
| Any 20-session window (baseline) | -2.6% | 44% |
Computed by MarketWall from daily closing prices since June 30, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquabl…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 888
- Website
- www.procept-biorobotics.com/
Fundamentals
- 1-day range
- $17.75$18.67
- Market cap
- $1.14B
- P/E (trailing)
- —
- P/E (forward)
- -15.22
- EPS (trailing)
- $-1.95
- Dividend yield
- —
- Beta
- 0.88
- Avg. volume
- 1.43M
How PROCEPT BioRobotics Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
PROCEPT BioRobotics Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- PRCTPROCEPT BioRobotics Corporation Common Stock$17.57▼ 3.20%Market cap $1.14BP/E —$16.67$38.11
- DRTSAlpha Tau Medical Ltd. Ordinary Shares$12.29▼ 6.61%Market cap $1.14BP/E —$3.43$15.79
- IRMDiRadimed Corporation Common Stock$88.27▼ 1.23%Market cap $1.17BP/E 49.82$71.34$107.9
- BVSBioventus Inc. Class A Common Stock$13.3▼ 3.69%Market cap $1.17BP/E 21.32$6.46$15.89
- TNDMTandem Diabetes Care Inc. Common Stock$16.24▼ 1.69%Market cap $1.29BP/E —$12.26$29.65
- AORTArtivion Inc. Common Stock$21.78▼ 0.41%Market cap $1.29BP/E 117.64$19.16$48.25
- IARTIntegra LifeSciences Holdings Corporation Common Stock$13.21▼ 2.37%Market cap $1.33BP/E —$8.7$20.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics Corporation Common Stock | $1.14B | — | $17.57 | ▼ 3.20% | $16.67$38.11 |
| DRTS Alpha Tau Medical Ltd. Ordinary Shares | $1.14B | — | $12.29 | ▼ 6.61% | $3.43$15.79 |
| IRMD iRadimed Corporation Common Stock | $1.17B | 49.82 | $88.27 | ▼ 1.23% | $71.34$107.9 |
| BVS Bioventus Inc. Class A Common Stock | $1.17B | 21.32 | $13.3 | ▼ 3.69% | $6.46$15.89 |
| TNDM Tandem Diabetes Care Inc. Common Stock | $1.29B | — | $16.24 | ▼ 1.69% | $12.26$29.65 |
| AORT Artivion Inc. Common Stock | $1.29B | 117.64 | $21.78 | ▼ 0.41% | $19.16$48.25 |
| IART Integra LifeSciences Holdings Corporation Common Stock | $1.33B | — | $13.21 | ▼ 2.37% | $8.7$20.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- PROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board ChangeYahoo · 10/8/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30benzinga · 10/7/2026
- Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30Benzinga · 10/7/2026
- Does New Director and Discounting Lawsuit Change The Bull Case For PROCEPT BioRobotics (PRCT)?Yahoo · 10/6/2026
- THINK Surgical Appoints Rick McDowell as Vice President, SalesYahoo · 9/22/2026
Insider Activity
Insider Actions →- Mack Michael · October 2, 2026 · Grant12.2K
- Mack Michael · October 2, 2026 · Grant7.7K
- Waters Kevin · September 9, 2026 · Sale373 @ $20.95
- Nouri Alaleh · September 9, 2026 · Sale297 @ $20.95
- Templin Barry L · September 9, 2026 · Sale373 @ $20.95
- Nouri Alaleh · August 13, 2026 · Grant31.8K
- Nouri Alaleh · August 13, 2026 · Grant23.0K
- Templin Barry L · August 13, 2026 · Grant36.3K
- Templin Barry L · August 13, 2026 · Grant26.2K
- Waters Kevin · August 13, 2026 · Grant40.9K
- Waters Kevin · August 13, 2026 · Grant29.5K
- Sharma Pooja · August 13, 2026 · Grant32.7K
- Sharma Pooja · August 13, 2026 · Grant23.6K
- Wood Larry L · August 7, 2026 · Buy23.9K @ $20.85
- Garrett Mary · June 9, 2026 · Grant3.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 53.42M
- Total value held
- $1.22B
- Institutional holders
- 251
- Unknown4.36M
- Unknown3.27M
- Unknown3.09M
- Unknown2.40M
- Unknown2.16M
- Unknown1.95M
- Unknown1.72M
- Unknown1.53M
- Unknown1.46M
- Unknown1.36M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
PROCEPT BioRobotics Sets Q3 2026 Earnings Date for Nov 4
PROCEPT BioRobotics has announced it will release its third-quarter 2026 financial results on November 4, 2026. This scheduled update provides investors with a specific date to review the company's recent performance. The announcement serves as a standard corporate disclosure ahead of the earnings release.
PROCEPT BioRobotics Sets Q3 2026 Earnings Date for Nov 4. PROCEPT BioRobotics has announced it will release its third-quarter 2026 financial results on November 4, 2026. This scheduled update provides investors with a specific date to review the company's recent performance. The announcement serves as a standard corporate disclosure ahead of the earnings release.